Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
| Status: | Archived |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2008 |
A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Hydroxychloroquine may help docetaxel work better and kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel together with
hydroxychloroquine works in treating patients with metastatic prostate cancer.
OBJECTIVES:
Primary
- To assess the antitumor activity, in terms of tumor response rate, of docetaxel in
combination with hydroxychloroquine in patients with metastatic, hormone-refractory,
chemotherapy-naive prostate cancer.
Secondary
- To measure time to disease progression and overall survival.
- To determine the feasibility and safety of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral hydroxychloroquine twice daily on days 1-21 and docetaxel IV over 1
hour on day 1. Treatment repeats every 21 days (up to 6 courses with docetaxel) in the
absence of disease progression or unacceptable toxicity.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Morristown Memorial Hospital Atlantic Health System – comprised of Morristown Medical Center, Overlook Medical Center,...
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Click here to add this to my saved trials
Click here to add this to my saved trials